
Given subcutaneously every 3 months, cemdisiran (Livsayis) is indicated for adults with AChR antibody–positive gMG and requires REMS enrollment.
Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses optimal support for distribution of specialty therapies.
Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses optimal support for distribution of specialty therapies.